Ifosfamide

Generic Name
Ifosfamide
Brand Names
Ifex
Drug Type
Small Molecule
Chemical Formula
C7H15Cl2N2O2P
CAS Number
3778-73-2
Unique Ingredient Identifier
UM20QQM95Y
Background

Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent.

Indication

Used as a component of various chemotherapeutic regimens as third-line therapy for recurrent or refractory germ cell testicular cancer. Also used as a component of various chemotherapeutic regimens for the treatment of cervical cancer, as well as in conjunction with surgery and/or radiation therapy in the treatment of various soft tissue sarcomas. Other indi...

Associated Conditions
Bladder Cancer, Cervical Cancer, Ewing's Sarcoma, Head And Neck Cancer, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma (NHL), Osteosarcoma, Ovarian Cancer, Pancreatic Cancer, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Testicular Germ Cell Cancer, Thymoma
Associated Therapies
-
Clinical Trials
Related News

Timing of Surgery in Nonmetastatic Osteosarcoma of the Pelvis and Sacrum

First Posted Date
2017-12-04
Last Posted Date
2018-08-28
Lead Sponsor
Peking University People's Hospital
Target Recruit Count
100
Registration Number
NCT03360760
Locations
🇨🇳

Peking University People's Hospital, Beijing, Beijing, China

Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and Adolescents

First Posted Date
2017-11-21
Last Posted Date
2018-12-11
Lead Sponsor
Gilead Sciences
Registration Number
NCT03349346
Locations
🇮🇹

Infantile Regina Margherita Hospital, Torino, Italy

🇮🇹

Istituto Giannina Gaslini, Genova, Italy

🇫🇷

Centre Hospitalier Régional Universitaire de Lille, Lille, France

and more 4 locations

A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma

First Posted Date
2017-09-14
Last Posted Date
2020-09-10
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
24
Registration Number
NCT03283696
Locations
🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

🇺🇸

University of Miami School of Medicine, Miami, Florida, United States

🇩🇪

Universitätsklinikum Essen, Essen, Nordrhein-Westfalen, Germany

and more 3 locations

Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas

First Posted Date
2017-09-11
Last Posted Date
2024-08-13
Lead Sponsor
Grupo Espanol de Investigacion en Sarcomas
Target Recruit Count
197
Registration Number
NCT03277924
Locations
🇮🇹

Istituto Nazionale dei Tumori, Milano, Italy

🇪🇸

Hospital Universitario Virgen del Rocío, Sevilla, Spain

🇪🇸

Hospital Universitari i Politècnic La Fe, Valencia, Spain

and more 10 locations

Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents

First Posted Date
2017-07-02
Last Posted Date
2023-12-11
Lead Sponsor
University Hospital Muenster
Target Recruit Count
650
Registration Number
NCT03206671
Locations
🇫🇮

Turku University Hospital, Paediatric and Adolescent Haematology and Oncology, Turku, Finland

🇨🇭

Universitäts-Kinderspital, Pädiatrische Onkologie, Zürich, Switzerland

🇨🇭

Kinderspital Pädiatrische Hämatologie/ Onkologie, Luzern, Switzerland

and more 89 locations

Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

First Posted Date
2017-03-13
Last Posted Date
2023-06-02
Lead Sponsor
Northwestern University
Target Recruit Count
43
Registration Number
NCT03077828
Locations
🇺🇸

Winship Cancer Institute of Emory University, Atlanta, Georgia, United States

🇺🇸

Augusta University Medical Center, Augusta, Georgia, United States

🇺🇸

Hackensack University Medical Center, Hackensack, New Jersey, United States

and more 3 locations

Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas

First Posted Date
2017-03-07
Last Posted Date
2018-06-11
Lead Sponsor
The University of Hong Kong
Target Recruit Count
50
Registration Number
NCT03071822
Locations
🇭🇰

The University of Hong Kong, Hong Kong, Hong Kong

Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

First Posted Date
2017-02-27
Last Posted Date
2022-11-16
Lead Sponsor
Molly Gallogly
Target Recruit Count
65
Registration Number
NCT03064867
Locations
🇺🇸

University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

🇺🇸

Washington University School of Medicine, Siteman Cancer Center, Saint Louis, Missouri, United States

🇺🇸

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

A Phase I Clinical Study for Evaluating the Safety and Efficacy of MASCT-I in Patients With Advanced Solid Tumors

First Posted Date
2017-01-27
Last Posted Date
2022-12-30
Lead Sponsor
HRYZ Biotech Co.
Target Recruit Count
193
Registration Number
NCT03034304
Locations
🇨🇳

Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China

🇨🇳

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

🇨🇳

Zhongshan Hospital Affiliated to Fudan University, Shanghai, Shanghai, China

and more 6 locations

Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL

First Posted Date
2017-01-11
Last Posted Date
2024-10-09
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
78
Registration Number
NCT03016871
Locations
🇺🇸

Yale University, New Haven, Connecticut, United States

🇺🇸

City of Hope Medical Center, Duarte, California, United States

🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

and more 1 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy